NCT02372097View on ClinicalTrials.gov

A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Healthy

Interventions

DRUG

SYR-472

SYR-472 25mg, 50mg

Trial Locations (1)

Unknown

Fukuoka

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY